Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need

Leal Therapeutics 宣布获得 3000 万美元 A 轮融资，用于推进针对高未满足需求的神经退行性和神经精神障碍的首创神经代谢疗法。

Leal Therapeutics is developing first-in-class therapeutics to correct metabolic imbalances in the brain for treatment of high unmet need CNS disorders

Leal Therapeutics正在开发首创的治疗方法，以纠正大脑中的代谢失衡，用于治疗高度未满足需求的中枢神经系统疾病。

Financing advances LTX-001 through clinical efficacy data in schizophrenia patients, LTX-002 through initial clinical data in ALS, and progresses additional pipeline programs

融资推动LTX-001在精神分裂症患者中获得临床疗效数据，LTX-002在ALS中获得初步临床数据，并推进其他管线项目。

WORCESTER, Mass., August 27, 2025-- Leal Therapeutics, Inc., a biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS), today announced a $30 million Series A financing. The round was led by SV Health Investors' Dementia Discovery Fund (DDF), in addition to existing investors OrbiMed, Newpath Partners, Chugai Venture Fund, Euclidean Capital, Alexandria Venture Investments, and PhiFund..

马萨诸塞州伍斯特市，2025年8月27日——Leal Therapeutics, Inc.是一家致力于为中枢神经系统（CNS）疾病患者开发新型疗法的生物技术公司，今天宣布完成了3000万美元的A轮融资。本轮融资由SV Health Investors的痴呆症发现基金（DDF）领投，现有投资者OrbiMed、Newpath Partners、中外制药风险基金、欧几里得资本、Alexandria Venture Investments和PhiFund也参与其中。

Leal's approach is rooted in the core principle that correcting metabolic imbalances in the brain is key to the development of effective therapies for patients living with neuropsychiatric or neurodegenerative disorders. This approach is supported by extensive human genetics, human biomarker, and preclinical model data.

莱亚尔的方法基于一个核心原则，即纠正大脑中的代谢失衡是为患有神经精神疾病或神经退行性疾病患者开发有效疗法的关键。这一方法得到了广泛的人类遗传学、人类生物标志物和临床前模型数据的支持。

Leal's lead program, LTX-001, is a clinical-stage, first-in-class brain-penetrant oral small molecule targeting excessive glutamate by inhibiting the mitochondrial enzyme glutaminase, for patients with psychiatric disorders including schizophrenia, Bipolar Disorder, Major Depressive Disorder as well as amyotrophic lateral sclerosis (ALS).

Leal公司的主导项目LTX-001是一种临床阶段的首创可穿透大脑的口服小分子药物，通过抑制线粒体酶谷氨酰胺酶来靶向过量的谷氨酸，用于治疗包括精神分裂症、双相情感障碍、重度抑郁症以及肌萎缩侧索硬化症（ALS）在内的精神疾病患者。

Data from an initial clinical study of LTX-001 support safety and effective target engagement. Leal is also developing LTX-002, a near-clinical stage antisense oligonucleotide (ASO) for patients with genetic or sporadic ALS. LTX-002 targets the de novo synthesis of ceramides/sphingolipids by inhibiting the first and rate-limiting enzyme in this pathway, SPT, and more specifically the SPTLC1 subunit.

LTX-001的初步临床研究数据支持其安全性和有效的靶点结合。Leal公司还在开发LTX-002，这是一种接近临床阶段的反义寡核苷酸（ASO），用于治疗遗传性或散发性ALS患者。LTX-002通过抑制该途径中的第一个且限速的酶SPT，更具体地说是SPTLC1亚基，来靶向从头合成神经酰胺/鞘脂类物质。

Excessive ceramides/sphingolipids are implicated in ALS and other neurodegenerative disorders. Leal is also developing LTX-007, a small molecule inhibitor of SPT, for neurodegenerative disorders such as Alzheimer's disease, ALS and inherited sphingolipidoses. In addition to the programs above, Leal is advancing next-generation technology to optimize delivery of nucleic acid therapeutics to the CNS through the blood brain barrier (BBB) using antibody-like shuttles.

过量的神经酰胺/鞘脂与ALS和其他神经退行性疾病有关。Leal公司还在开发LTX-007，一种SPT的小分子抑制剂，用于治疗阿尔茨海默病、ALS和遗传性鞘脂沉积症等神经退行性疾病。除了上述项目外，Leal公司还在推进下一代技术，利用抗体样穿梭物优化通过血脑屏障（BBB）向中枢神经系统递送核酸药物。

.

。

Proceeds from the Series A financing will be used to advance LTX-001 through a clinical trial in schizophrenia patients, as well as progress LTX-002 through initial clinical data in ALS. 'This financing enables us to further progress our first-in-class neuro-metabolic pipeline to clinical data for patients with severe unmet needs,' said Asa Abeliovich, M.D., Ph.D., founder and chief executive officer of Leal.

A轮融资的收益将用于推动LTX-001在精神分裂症患者中的临床试验，以及推进LTX-002在ALS中的初步临床数据。Leal创始人兼首席执行官Asa Abeliovich博士表示：“此次融资使我们能够进一步推进我们首创的神经代谢管线，为具有严重未满足需求的患者获取临床数据。”

'We're grateful to our new and existing investors for their shared commitment to advancing this work.'.

“我们感谢新老投资者对推进这项工作的共同承诺。”

In connection with the financing, Christian Jung, Ph.D., Partner at SV Health Investors, joined Leal's board of directors. 'Leal is advancing promising and highly differentiated programs for CNS disorders with a clear clinical strategy and a uniquely qualified team,' said Dr. Jung. 'We believe the company is well-positioned to make significant strides in the treatment of neurodegenerative and neuropsychiatric diseases.

与融资相关，SV Health Investors的合伙人克里斯蒂安·容博士加入了Leal的董事会。容博士表示：“Leal正在推进针对中枢神经系统疾病的前景广阔且高度差异化的项目，具有明确的临床策略和一支独特资质的团队。我们相信，该公司在神经退行性和神经精神疾病治疗领域具备良好优势，能够取得重大进展。”

We're proud to support Leal as they take this next critical step.'.

我们很自豪能够支持Leal迈出这一关键的下一步。

About Leal Therapeutics:

关于Leal Therapeutics：

Leal Therapeutics is a biotechnology company dedicated to developing novel neuro-metabolic therapeutics for patients with high-need central nervous system disorders. Leal was launched in 2021 and is headquartered in Worcester, Mass. Leal's lead programs address the critical intersection between CNS and metabolic disorders.

Leal Therapeutics是一家生物技术公司，致力于为中枢神经系统疾病高需求患者开发新型神经代谢治疗药物。Leal于2021年成立，总部位于马萨诸塞州伍斯特市。Leal的主要项目针对中枢神经系统疾病和代谢紊乱之间的关键交汇点。

The Leal team has particular expertise in CNS therapeutic development, as well as leveraging human genetics, functional genomics and biomarker analyses to support our mission. Leal has the technological capability to develop and produce small molecule as well as nucleic acid CNS therapeutics at scale..

Leal团队在中枢神经系统（CNS）治疗开发方面具有特殊的专业知识，并且擅长利用人类遗传学、功能基因组学和生物标志物分析来支持我们的使命。Leal具备开发和规模化生产小分子以及核酸类CNS治疗药物的技术能力。

About SV Health Investors' Dementia Discovery Fund

关于SV健康投资者的痴呆症发现基金

SV Health Investors' Dementia Discovery Fund (DDF) is the world's largest family of specialized venture capital funds that invests exclusively in companies developing or enabling novel therapeutics for dementia. Dementias including Alzheimer's Disease are arguably the largest unmet medical need with over 55m patients worldwide.

SV Health Investors的痴呆症发现基金（DDF）是全球最大的专业风险投资基金家族，专门投资于开发或支持新型痴呆症治疗药物的公司。包括阿尔茨海默病在内的痴呆症可以说是目前最大的未满足医疗需求，全球患者超过5500万。

With more than $600m raised for this strategy, and offices in London and Boston, DDF capitalizes on global investment opportunities to fulfill its dual mandate of delivering measurable impact and generating significant financial returns. Utilizing its network of venture partners, entrepreneurs, leading scientists, and strategic partners, DDF invests in and creates new biotech companies and provides thought leadership in the field.

DDF 已为这一战略筹集了超过 6 亿美元，并在伦敦和波士顿设有办事处，利用全球投资机会实现其产生可衡量影响和创造显著财务回报的双重使命。通过其风险合伙人、企业家、顶尖科学家和战略合作伙伴网络，DDF 投资并创建新的生物技术公司，同时在该领域提供思想领导力。

DDF is enabled by its cornerstone investors AARP, the British Business Bank and Gates Frontier, as well as additional limited partners, including major pharmaceutical companies and leading non-profits. For more information, please visit https://svhealthinvestors.com/DDF..

DDF 由其基石投资者 AARP、英国商业银行和 Gates Frontier 以及包括主要制药公司和领先非营利组织在内的其他有限合伙人支持。欲了解更多信息，请访问 https://svhealthinvestors.com/DDF。

About SV Health Investors

关于SV健康投资者

SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow's healthcare breakthroughs. The SV funds invest across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, medical devices, healthcare growth and healthcare technology. With more than $2bn in assets under management, and historical commitments in excess of $4bn, SV has built an extensive network of talented investment professionals and experienced industry veterans and a truly transatlantic presence with offices in London and Boston.

SV Health Investors 是一家领先的医疗保健基金管理公司，致力于投资未来的医疗突破。SV 基金跨阶段、跨地区、跨领域进行投资，专业领域涵盖生物技术、痴呆症、医疗器械、医疗增长和医疗技术。凭借超过 20 亿美元的管理资产和历史上超过 40 亿美元的投资承诺，SV 汇聚了众多才华横溢的投资专业人士和经验丰富的行业资深人士，并在伦敦和波士顿设有办事处，建立了真正的跨大西洋业务网络。

Since its founding in 1993, SV has invested in, created and built more than 200 companies attracting global talent, entrepreneurs and pharma partners. To date, these investments have resulted in the licensing of 28 novel drugs and six new drug classes able to treat indications with unmet medical needs and deliver positive impact to patients.

自 1993 年成立以来，SV 已投资、创建和打造了 200 多家公司，吸引全球人才、企业家和制药合作伙伴。迄今为止，这些投资已促成 28 种新型药物和六种新药类别的授权，能够治疗未满足医疗需求的病症，并为患者带来积极影响。

For more information, please visit https://svhealthinvestors.com..

有关更多信息，请访问 https://svhealthinvestors.com。

Contact:

联系人：

Media contact:

媒体联系人：

Tehya Frank

特哈亚·弗兰克

atr@karv.global

atr@karv.global

347-640-1334

347-640-1334